Clinical-Grade AFE from Analog Devices Measures Four Vital Signs for Remote Patient Monitoring Devices

The MAX86178 Enables Synchronized Optical PPG and ECG Timing for Derived Health Metrics

Simplify the design of wearable remote patient monitoring (RPM) devices by measuring four vital signs with one MAX86178 triple-system vital signs analog front end (AFE) from Analog Devices, Inc.

This single-chip AFE integrates three measurement systems (optical, ECG and bio-impedance) to obtain four common vital signs: electrocardiogram (ECG or EKG), heart rate (ECG or optical PPG), blood-oxygen saturation (SpO2) and respiration rate (using BioZ). The MAX86178 enables synchronized optical PPG and ECG timing for derived health metrics.

  • View the MAX86178 triple-system vital signs AFE product page, download the datasheet and order samples: https://bit.ly/MAX86178_Product
  • Download a high-resolution image: https://bit.ly/Image_MAX86178
  • Connect with engineers and ADI product experts on EngineerZone™, an online technical support community: https://ez.analog.com

Medical device designers are eager to reduce annual healthcare-related expenditures by replacing office-based health monitoring systems with smaller, lower power, wireless devices worn discreetly and continuously in the home or office. With three clinical-grade subsystems integrated into one IC, the MAX86178 triple system AFE replaces discrete implementations by integrating an optical PPG sub-system to measure heart rate and SpO2, a single lead ECG sub-system, as well as a biopotential and bioimpedance (BioZ) sub-system to measure respiration rate. It permits small vital signs devices by fitting those multiple functions into a 2.6mm x 2.8mm package.

In addition, next-generation wearable RPMs need to operate at low power to permit smaller batteries or extend battery life to allow more convenient charging requirements. To enable ultra-low power features, the MAX86178 provides each subsystem with configurable options to optimize battery life for specific use cases.

“By integrating three healthcare subsystems on one piece of silicon, Analog Devices builds on its DNA and delivers this sensor-fusion product,” said Andrew Burt, Executive Business Manager of the Industrial and Healthcare Business Unit at Maxim Integrated®, now part of Analog Devices. “This AFE is resonating with the medical community because it presents new possibilities for chronic disease management, contagious disease diagnosis and remote monitoring. The MAX86178 enables small body-worn devices that can improve healthcare delivery and lower costs by keeping people out of the hospital.”

In addition, Analog Devices offers the MAX20343 buck-boost regulator and the MAX20360 power management IC as power solutions optimized for the MAX86178.

MAX86178 Triple-System Vital Signs AFE Features and Benefits

  • Small Size: Replaces medical facility grade monitoring systems with body-worn devices
  • Simplified Design: By integrating and synchronizing three different measurement systems to measure four vital signs, it simplifies design and enables even more complicated derivative vital signs monitoring

Availability

Product

Availability

Packaging

MAX86178

Now

2.6mm x 2.8mm WLP package 

MAX86178EVKIT#

Now

N/A

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”